On February 22, 2016, in the second federal appellate drug patent settlement ruling since the Supreme Court’s decision in FTC v. Actavis, 133 S. Ct. 2223 (2013), the U.S. Court of Appeals for the First Circuit vacated a lower court decision granting a motion to dismiss for defendants. Writing for a unanimous panel, Judge Juan Torruella unequivocally found that Actavis applied to not only cash payments but also other forms of consideration. Factual background The case involves oral contraceptive Loestrin 24. Earlier versions of Loestrin required patients to take tablets for 21 straight days, followed by a week of placebo pills (or skipped tablets). In re Loestrin 24 FE Antitrust Litigation, 2016 WL 698077, at *4 (1st Cir. Feb. 22, 2016) (Loestrin). Users of these earlier Loestrin
Share on
|
|
The US Court of Appeals for the First Circuit concludes that a reverse payment need not be in cash (Loestrin)
Access to this article is restricted to subscribers
Already Subscribed? Sign-in
Access to this article is restricted to subscribers.
Read one article for free
Sign-up to read this article for free and discover our services.
